



# Biotech Daily

Thursday June 9, 2016

*Daily news on ASX-listed biotechnology companies*

- \* **ASX DOWN, BIOTECH EVEN: LIVING CELL UP 9%; ANTISENSE DOWN 10%**
- \* **PARADIGM READY FOR PHASE I PPS FOR HAY FEVER TRIAL**
- \* **NUHEARA IQBUDS PRE-ORDER HITS \$1m**
- \* **BPH, CORTICAL DYNAMICS APPOINTS DISTRIBUTOR**
- \* **RESPIRI (ISONEA) AIMS AT POLLUTED CHINA, INDIA MARKETS**
- \* **TDM TAKES 6% OF SOMNOMED**
- \* **CYNATA APPOINTS DR PAUL WOTTON DIRECTOR**
- \* **NEW SCIGEN DIRECTOR DR MAREK DZIKI APPOINTED CHAIRMAN**

## MARKET REPORT

The Australian stock market fell 0.15 percent on Thursday June 9, 2016 with the ASX200 down 8.1 points to 5,361.9 points.

Fifteen of the Biotech Daily Top 40 stocks were up, 14 fell, nine traded unchanged and two were untraded.

Living Cell was the best, up 0.5 cents or 8.6 percent to 6.3 cents with 628,707 shares traded.

Compumedics climbed 7.5 percent; Biotron and Opthea were up more than six percent; Avita, Cellmid and Prima improved more than four percent; Airxpanders, IDT and Viralytics were up more than three percent; Pro Medicus and Uscom rose two percent or more; Bionomics, Prana and Starpharma were up more than one percent; with Cochlear and Resmed up by less than one percent.

Antisense led the falls, down 0.4 cents or 9.8 percent to 3.7 cents with 138,840 shares traded.

Clinuvel fell 4.55 percent; Actinogen, Neuren, Polynovo and Universal Biosensors were down more than three percent; Osprey shed 2.1 percent; Admedus, Impedimed, Medical Developments and Nanosonics were down one percent or more; with Acrux, CSL, Reva and Sirtex down by less than one percent.

## PARADIGM BIOPHARMACEUTICALS

Paradigm says it has ethics approval for a phase I trial of pentosan polysulfate sodium for hay fever expected to begin on June 20 and be completed on August 30, 2016.

Paradigm said that in a pre-clinical toxicology study, rats were dosed twice daily for 28 days at three dose levels and pentosan polysulfate sodium (PPS) was safe and well tolerated, with no adverse effects.

The company said that the 18-patient phase I trial would deliver pentosan polysulfate sodium intra-nasally for the first time in healthy human volunteers.

Paradigm said that the double blind, randomized, placebo-controlled trial would dose two cohorts of nine subjects per cohort with a single dose, followed by a seven day multiple dose regime.

The company said that the subjects would remain in the clinical trial unit during dosing and have comprehensive safety monitoring.

Paradigm said that recruitment was continuing for its 40-patient, phase II trial of the Zilosul formulation of pentosan polysulfate sodium for bone marrow oedema from acute injury, such as ruptured anterior cruciate ligaments, with an interim analysis planned for December 2016 (BD: Feb 23, Mar 2, 2016).

Paradigm was up three cents or 9.4 percent to 35 cents.

## NUHEARA

Nuheara says its Iqbuds pre-order campaign has passed \$1,000,000 for 3,632 sets of its sound filtering and device ear buds.

Nuheara said that the 60-day Indiegogo platform campaign closed on June 3, 2016 with orders from more than 3,300 customers in 80 countries, but Iqbuds would remain available for pre-order.

In April Nuheara said it had crowd-sourced orders worth \$US393,428 (\$A513,747) for its Iqbud ear buds in two weeks (BD: Apr 18, 2016).

Nuheara co-founder and head of sales and marketing David Cannington said that "consumer excitement about Iqbuds is what has driven the success of the Indiegogo pre-order campaign".

"Most importantly, the campaign indicates there is a global opportunity for Iqbuds given that we received orders from 80 countries and have been approached by distributors and resellers around the globe who want to partner with Nuheara," Mr Cannington said.

"Based on the pre-orders received, the US will clearly be a major market and its advantageous the company already has a sales and marketing presence in San Francisco to drive this side of the business," Mr Cannington said.

Nuheara fell 0.4 cents or 4.55 percent to 8.4 cents with 14.4 million shares traded.

## BPH ENERGY

BPH says that investee company Cortical Dynamics has a letter of intent for Device Technologies Australia to distribute its brain anaesthesia response (BAR) monitor.

BPH said that the Sydney-based Device Technologies Australia would have exclusive distribution rights for Australia and New Zealand for six months and subject to market assessment it would have the right to continue exclusive distribution rights for an additional four years and six months.

In February, BPH said it held 3.89 percent of Cortical Dynamics and could increase to more than 10 percent through the conversion of a secured loan (BD: Feb 17, 2016).

BPH was untraded at 0.7 cents.

### RESPIRI (FORMERLY ISONEA)

Respiri says that air pollution in China and India causing asthma and respiratory diseases made them “a major opportunity for Respiri’s wheeze monitoring products”.

Respiri chairman Leon L’Huillier said he presented at the 121 Tech Investment conference in Hong Kong and “conference participants acknowledged that air pollution in the huge markets of China and India is generally recognised as a major cause of asthma and other respiratory problems”.

The company said that the two markets were “a major opportunity for Respiri’s wheeze monitoring products”.

Respiri said that it received “strong interest from a number of major health industry participants and institutional investors including proposals of opportunities in Asia” which it would advance following the completion of the current fully-underwritten \$4.3 million rights issue (BD: May 19, 2016).

Last year, Isonesa said that and announced a 90-patient US trial of its Airsonesa asthma diagnostic which it expected to complete by the end of 2015 (BD: Aug 12, Nov 25, 2015).

Also last year, the company announced the departure of its fourth chief executive officer in 12 months (BD: Jan 23, 2015).

Respiri was up half a cent or 15.6 percent to 3.7 cents with 1.7 million shares traded.

### SOMNOMED

TDM Asset Management has increased its holding in Somnomed from 2,654,895 shares (5.06%) to 3,610,966 shares (6.37%).

The New York-based TDM said it acquired 956,071 shares at \$2.74 a share in a “pro-rata entitlement offer and shortfall [and] on-market transactions”.

Somnomed was up seven cents or 2.2 percent to \$3.28.

### CYNATA THERAPEUTICS

Cynata says it has appointed Dr Paul Wotton as a director.

Cynata said that Dr Wotton had “an outstanding track record of leading companies to clinical, financial and commercial success, most recently demonstrated in his stewardship of Ocata Therapeutics ... culminating in the recent acquisition of that company by Astellas Pharma in a \$US379 million all cash transaction”.

The company said that Dr Wotton had more than 30 years experience in the pharmaceuticals and biotechnology industry and was formerly Antares Pharma chief executive officer and was currently a director of the US-based Vericel Corp.

Cynata said Dr Wotton held a Doctorate of Philosophy from the University of Nottingham and a Masters of Business Administration from London’s Kingston Business School.

Cynata fell half a cent or 1.4 percent to 35 cents.

### SCIGEN

Scigen says that Dr Marek Dziki who was appointed as a director earlier this week has been appointed as chairman (BD: Jun 7, 2016).

Scigen was unchanged at one cent.